EAM
EWTX icon

Eventide Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Eventide Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-149,863
Closed -$4.72M – 319
2026
Q1 		$4.72M Sell
149,863
-418,447
-74% -$12.1M 0.08% 164
2025
Q4 		$14.1M Hold
568,310
– – 0.22% 121
2025
Q3 		$9.22M Hold
568,310
– – 0.15% 132
2025
Q2 		$7.45M Hold
568,310
– – 0.13% 135
2025
Q1 		$12.5M Buy
+568,310
New +$14.9M 0.25% 117

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Eventide Asset Management's EWTX Position: Q2 2026 in Review

Eventide Asset Management sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 149,863 shares — an estimated $4.72M sold.

Eventide Asset Management first reported a position in EWTX in Q1 2025 and held it in 5 quarters. The position peaked at $14.1M in Q4 2025. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Eventide Asset Management reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Eventide Asset Management sold 149,863 Edgewise Therapeutics shares in Q2 2026, an estimated $4.72M.
  • Eventide Asset Management first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 5 quarters.
  • Eventide Asset Management's Edgewise Therapeutics position peaked at $14.1M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.